drugset / Trial / NCT06319534

Stellate Ganglion Block in Bulbar Palsy

NCT06319534 ↗

Completed 124 enrolled Zeng Xi
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized controlled study, including dysphagic patients with bulbar palsy after ischemic stroke who were received in the department of rehabilitation medicine in 3 hospitals in China. All patients are randomly allocated to the observation group or the control group. Both groups are provided with comprehensive rehabilitation. Besides, the observation group additionally undergoes the stellate ganglion block. At admission and after 10-day treatment, video fluoroscopic swallowing study, ultrasound diagnostic devices, and penetration-aspiration scale, Flexible laryngoscope are used to assess swallowing function.

Timeline

Start
2024-03-23
Primary completion
2025-06-05
Completion
2025-07-05

Outcome

Met primary endpoint

paper SGB is safe and can effectively improve swallowing function, airway protection, and anxiety. PMID 41782152 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 2.8 ml Other

Indications

No indication recorded.